Contineum Therapeutics Inc(CTNM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:26 PM ET (Korea 10/31 05:26)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.74 | Insider Own | 21.27% | Shs Outstand | 33.0M | Perf Week | 13% |
| Market Cap | 0.35B | Forward P/E | - | EPS next Y | -16.84% | Insider Trans | -0.93% | Shs Float | 29.6M | Perf Month | -27.71% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | -0.45 | Inst Own | 81.24% | Short Float | 12.34% | Perf Quarter | -41.05% |
| Income | -0.06B | P/S | - | EPS this Y | 21.31% | Inst Trans | 0.22% | Short Ratio | 4.42 | Perf Half Y | -28.86% |
| Sales | 0.00B | P/B | 1.47 | EPS next 5Y | 2.63% | ROA | -26.57% | Short Interest | 3.66M | Perf YTD | -17.85% |
| Book/sh | 6.37 | P/C | 1.49 | EPS past 3/5Y | -30.91% - | ROE | -28.01% | 52W High | -47.2% ($17.78) | Perf Year | -10.91% |
| Cash/sh | 6.29 | P/FCF | - | Sales past 3/5Y | - | ROIC | -23.6% | 52W Low | 39.63% ($6.72) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 21.01% | Gross Margin | - | Volatility(W/M) | 8.98% 10.4% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.97 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 37.17 | EPS Q/Q | 34.71% | Profit Margin | - | RSI (14) | 43.03 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 37.17 | Sales Q/Q | - | SMA20 | -1.53% ($9.54) | Beta | 0.91 | Target Price | $22.14 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/7/30 | SMA50 | -26.08% ($12.7) | Rel Volume | 0.55 | Prev Close | $9.33 |
| Employees | 51 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 10.87% - | SMA200 | -30.72% ($13.55) | Avg Volume(3M) | 0.83M | Price | $9.39 |
| IPO | 2024/4/5 | Option/Short | Yes/Yes | Trades | 3813 | Volume | 458,631 | Change | 0.64% |
🧬 This is a US-based clinical-stage biotech developing small-molecule drugs in the fields of neuroscience and immunology. Its core pipeline includes LPA receptor antagonists and muscarinic receptor inhibitors, and it is running clinical trials targeting indications with significant unmet needs such as idiopathic pulmonary fibrosis, multiple sclerosis, chronic pain, and major depressive disorder.
Over the past 1 year, on the lower side
47% below its 1-year high.
Traded less than usual. That is 55% of its average volume.
CTNM has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +21.3% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 81.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #249 of 597 in the industry
Based on market cap of $353M.
FENC#247 Fennec Pharmaceuticals Inc $359M PER - 
OBIO#248 Orchestra BioMed Holdings Inc $355M PER - CTNM#249 Contineum Therapeutics Inc $353M PER - 
KYTX#250 Kyverna Therapeutics Inc $351M PER - 
NAUT#251 Nautilus Biotechnology Inc $348M PER - 
FAQ
What kind of company is CTNM?
CTNM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CTNM?
The market cap of CTNM is approximately $353M, ranking 3,460 within its sector.
What is the 52-week high and low for CTNM?
CTNM has recorded a 52-week high of $17.78 and a low of $6.72.
